Elite Pharmaceuticals, Inc. — Second Quarter Fiscal Year 2027 Earnings Summary

Elite Pharmaceuticals, Inc. reported consolidated revenues of $40.1 million for the second quarter of fiscal year 2027, representing a 10.4% increase from the prior year period. This growth was primarily driven by higher sales from the company's amphetamine and naltrexone product lines under the Elite label. The company recorded income from operations of $9.9 million and net income attributable to common shareholders of $17.3 million for the quarter. Management is scheduled to host a conference call on November 13, 2026, to discuss these financial results and recent business developments.